The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antisense Oligonucleotide Drugs(ASO Drugs) Market Research Report 2025
Synopsis
A class of molecular drugs that inhibit gene expression and regulate at the gene level through sequence specific binding with target gene DNA or mRNA
Global Antisense Oligonucleotide Drugs(ASO Drugs) market is projected to reach US$ 10870 million in 2029, increasing from US$ 2780 million in 2022, with the CAGR of 21.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Antisense Oligonucleotide Drugs(ASO Drugs) market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Antisense Oligonucleotide Drugs(ASO Drugs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Lonis
Biogen
Sarepta
Novartis
Antisense Therapeutics
Akcea
Ruibo Bio
Inois
Therapeutics Inc.
Sanofi
Segment by Type
Steric Hindrance
RNA Degradation
RNA Splicing Regulation
Segment by Application
Hospital
Laboratory
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Antisense Oligonucleotide Drugs(ASO Drugs) report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
A class of molecular drugs that inhibit gene expression and regulate at the gene level through sequence specific binding with target gene DNA or mRNA
Global Antisense Oligonucleotide Drugs(ASO Drugs) market is projected to reach US$ 10870 million in 2029, increasing from US$ 2780 million in 2022, with the CAGR of 21.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Antisense Oligonucleotide Drugs(ASO Drugs) market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Antisense Oligonucleotide Drugs(ASO Drugs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Lonis
Biogen
Sarepta
Novartis
Antisense Therapeutics
Akcea
Ruibo Bio
Inois
Therapeutics Inc.
Sanofi
Segment by Type
Steric Hindrance
RNA Degradation
RNA Splicing Regulation
Segment by Application
Hospital
Laboratory
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Antisense Oligonucleotide Drugs(ASO Drugs) report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Antisense Oligonucleotide Drugs(ASO Drugs) Market Overview
1.1 Product Overview and Scope of Antisense Oligonucleotide Drugs(ASO Drugs)
1.2 Antisense Oligonucleotide Drugs(ASO Drugs) Segment by Type
1.2.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Market Value Comparison by Type (2023-2029)
1.2.2 Steric Hindrance
1.2.3 RNA Degradation
1.2.4 RNA Splicing Regulation
1.3 Antisense Oligonucleotide Drugs(ASO Drugs) Segment by Application
1.3.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Laboratory
1.3.4 Other
1.4 Global Antisense Oligonucleotide Drugs(ASO Drugs) Market Size Estimates and Forecasts
1.4.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue 2018-2029
1.4.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales 2018-2029
1.4.3 Global Antisense Oligonucleotide Drugs(ASO Drugs) Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Antisense Oligonucleotide Drugs(ASO Drugs) Market Competition by Manufacturers
2.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales Market Share by Manufacturers (2018-2023)
2.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Antisense Oligonucleotide Drugs(ASO Drugs) Average Price by Manufacturers (2018-2023)
2.4 Global Antisense Oligonucleotide Drugs(ASO Drugs) Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Antisense Oligonucleotide Drugs(ASO Drugs), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antisense Oligonucleotide Drugs(ASO Drugs), Product Type & Application
2.7 Antisense Oligonucleotide Drugs(ASO Drugs) Market Competitive Situation and Trends
2.7.1 Antisense Oligonucleotide Drugs(ASO Drugs) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antisense Oligonucleotide Drugs(ASO Drugs) Players Market Share by Revenue
2.7.3 Global Antisense Oligonucleotide Drugs(ASO Drugs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antisense Oligonucleotide Drugs(ASO Drugs) Retrospective Market Scenario by Region
3.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Region: 2018-2029
3.2.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Region: 2018-2023
3.2.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Region: 2024-2029
3.3 Global Antisense Oligonucleotide Drugs(ASO Drugs) Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Region: 2018-2029
3.3.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Region: 2018-2023
3.3.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Region: 2024-2029
3.4 North America Antisense Oligonucleotide Drugs(ASO Drugs) Market Facts & Figures by Country
3.4.1 North America Antisense Oligonucleotide Drugs(ASO Drugs) Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Country (2018-2029)
3.4.3 North America Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antisense Oligonucleotide Drugs(ASO Drugs) Market Facts & Figures by Country
3.5.1 Europe Antisense Oligonucleotide Drugs(ASO Drugs) Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Country (2018-2029)
3.5.3 Europe Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antisense Oligonucleotide Drugs(ASO Drugs) Market Facts & Figures by Country
3.6.1 Asia Pacific Antisense Oligonucleotide Drugs(ASO Drugs) Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Country (2018-2029)
3.6.3 Asia Pacific Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antisense Oligonucleotide Drugs(ASO Drugs) Market Facts & Figures by Country
3.7.1 Latin America Antisense Oligonucleotide Drugs(ASO Drugs) Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Country (2018-2029)
3.7.3 Latin America Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antisense Oligonucleotide Drugs(ASO Drugs) Market Facts & Figures by Country
3.8.1 Middle East and Africa Antisense Oligonucleotide Drugs(ASO Drugs) Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Country (2018-2029)
3.8.3 Middle East and Africa Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Type (2018-2029)
4.1.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Type (2018-2023)
4.1.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Type (2024-2029)
4.1.3 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales Market Share by Type (2018-2029)
4.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Type (2018-2029)
4.2.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Type (2018-2023)
4.2.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Type (2024-2029)
4.2.3 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue Market Share by Type (2018-2029)
4.3 Global Antisense Oligonucleotide Drugs(ASO Drugs) Price by Type (2018-2029)
5 Segment by Application
5.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Application (2018-2029)
5.1.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Application (2018-2023)
5.1.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Application (2024-2029)
5.1.3 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales Market Share by Application (2018-2029)
5.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Application (2018-2029)
5.2.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Application (2018-2023)
5.2.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Application (2024-2029)
5.2.3 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue Market Share by Application (2018-2029)
5.3 Global Antisense Oligonucleotide Drugs(ASO Drugs) Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Lonis
6.1.1 Lonis Corporation Information
6.1.2 Lonis Description and Business Overview
6.1.3 Lonis Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Lonis Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolio
6.1.5 Lonis Recent Developments/Updates
6.2 Biogen
6.2.1 Biogen Corporation Information
6.2.2 Biogen Description and Business Overview
6.2.3 Biogen Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Biogen Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolio
6.2.5 Biogen Recent Developments/Updates
6.3 Sarepta
6.3.1 Sarepta Corporation Information
6.3.2 Sarepta Description and Business Overview
6.3.3 Sarepta Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sarepta Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolio
6.3.5 Sarepta Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novartis Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Antisense Therapeutics
6.5.1 Antisense Therapeutics Corporation Information
6.5.2 Antisense Therapeutics Description and Business Overview
6.5.3 Antisense Therapeutics Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Antisense Therapeutics Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolio
6.5.5 Antisense Therapeutics Recent Developments/Updates
6.6 Akcea
6.6.1 Akcea Corporation Information
6.6.2 Akcea Description and Business Overview
6.6.3 Akcea Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Akcea Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolio
6.6.5 Akcea Recent Developments/Updates
6.7 Ruibo Bio
6.6.1 Ruibo Bio Corporation Information
6.6.2 Ruibo Bio Description and Business Overview
6.6.3 Ruibo Bio Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Ruibo Bio Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolio
6.7.5 Ruibo Bio Recent Developments/Updates
6.8 Inois
6.8.1 Inois Corporation Information
6.8.2 Inois Description and Business Overview
6.8.3 Inois Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Inois Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolio
6.8.5 Inois Recent Developments/Updates
6.9 Therapeutics Inc.
6.9.1 Therapeutics Inc. Corporation Information
6.9.2 Therapeutics Inc. Description and Business Overview
6.9.3 Therapeutics Inc. Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Therapeutics Inc. Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolio
6.9.5 Therapeutics Inc. Recent Developments/Updates
6.10 Sanofi
6.10.1 Sanofi Corporation Information
6.10.2 Sanofi Description and Business Overview
6.10.3 Sanofi Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Sanofi Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolio
6.10.5 Sanofi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antisense Oligonucleotide Drugs(ASO Drugs) Industry Chain Analysis
7.2 Antisense Oligonucleotide Drugs(ASO Drugs) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antisense Oligonucleotide Drugs(ASO Drugs) Production Mode & Process
7.4 Antisense Oligonucleotide Drugs(ASO Drugs) Sales and Marketing
7.4.1 Antisense Oligonucleotide Drugs(ASO Drugs) Sales Channels
7.4.2 Antisense Oligonucleotide Drugs(ASO Drugs) Distributors
7.5 Antisense Oligonucleotide Drugs(ASO Drugs) Customers
8 Antisense Oligonucleotide Drugs(ASO Drugs) Market Dynamics
8.1 Antisense Oligonucleotide Drugs(ASO Drugs) Industry Trends
8.2 Antisense Oligonucleotide Drugs(ASO Drugs) Market Drivers
8.3 Antisense Oligonucleotide Drugs(ASO Drugs) Market Challenges
8.4 Antisense Oligonucleotide Drugs(ASO Drugs) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
